Riskpilot← Back to searchSign inGet full accessAXIMED AS
ASActiveOrg 980363651Strandkaien 18, 5013 BergenOther business support service activities n.e.c. · NACE 8299Est. 19980 employees
Revenue 2024
NOK 783K
+11% vs 2023
EBITDA margin
5.9%
+256% vs 2023
Equity ratio
26.1%
Financial strength
Net profit 2024
NOK -496K
+58% vs 2023
| Revenue | NOK 783K | +11% |
| EBITDA | NOK 46K | +256% |
| Net profit | NOK -496K | +58% |
| Total assets | NOK 26,7M | +0% |
| Equity | NOK 7M | -7% |
| Employees | 0 | — |
Legal name
AXIMED AS
Org number
980363651
Legal form
Aksjeselskap
NACE code
8299 · Other business support service activities n.e.c.
Founded
9. desember 1998
Share capital
NOK 6 195 655
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap, eller daglig leder alene.
Company purpose
Produksjon, utvikling, eksport, import og engrosdistribusjon av kosttilskudd, naturlegemiddel og legemiddel, og produksjon og salg av giftfri malingstilsetning samt annen virksomhet som naturlig faller inn under dette.
Address
Strandkaien 18, 5013 Bergen
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 293 | 2 464 | 3 282 | 3 416 | 2 449 | 2 429 | 4 619 | 4 359 | 3 860 | 4 183 | 3 598 | 3 671 | 755 | 525 | 692 | 706 | 783 |
| Staff expenses | −1 253 | 1 911 | −1 073 | −1 070 | −761 | −728 | −868 | −1 172 | −1 113 | −1 171 | −1 030 | −580 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −70 | 3 143 | 117 | 619 | 320 | 271 | 1 068 | 208 | 249 | 123 | 385 | 47 | 58 | 135 | 84 | −29 | 46 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −2 | −14 | −15 | −22 | −27 | −31 | −25 | −15 | −10 | −10 | −7 |
| EBIT | −70 | 3 143 | 117 | 619 | 320 | 271 | 1 066 | 194 | 234 | 101 | 358 | 16 | 33 | 120 | 74 | −39 | 39 |
| Net financials | −2 | −156 | −7 | −611 | −158 | −507 | −704 | −2 335 | 1 293 | −827 | 378 | −6 | −1 542 | 1 196 | −1 445 | −1 150 | −535 |
| Profit before tax | −72 | 2 987 | 109 | 8 | 162 | −236 | 361 | −2 141 | 1 526 | −726 | 736 | 10 | −1 509 | 1 316 | −1 370 | −1 190 | −496 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −72 | 2 987 | 109 | 8 | 162 | −236 | 361 | −2 141 | 1 526 | −726 | 736 | 10 | −1 509 | 1 316 | −1 370 | −1 190 | −496 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 14 924 | 18 180 | 21 838 | 24 840 | 25 412 | 26 947 | 26 869 | 26 578 | 25 823 | 25 822 | 26 372 | 28 445 | 28 343 | 28 312 | 26 102 | 26 650 | 26 693 |
| Equity | 1 636 | 5 631 | 10 502 | 10 510 | 10 673 | 10 437 | 10 798 | 8 657 | 10 183 | 9 457 | 10 194 | 10 204 | 8 695 | 10 011 | 8 640 | 7 451 | 6 955 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 368 | 203 | 30 | 708 | 458 | 208 | 0 | 0 | 0 | 0 |
| Short-term debt | 13 288 | 12 549 | 11 336 | 14 330 | 14 739 | 16 510 | 16 071 | 17 553 | 15 437 | 16 335 | 15 470 | 17 783 | 19 440 | 18 301 | 17 462 | 19 200 | 19 738 |
| Total debt | 13 288 | 12 549 | 11 336 | 14 330 | 14 739 | 16 510 | 16 071 | 17 921 | 15 640 | 16 365 | 16 178 | 18 242 | 19 648 | 18 301 | 17 462 | 19 200 | 19 738 |
EBITDA margin
5.9%
This company
15.8%
Market median
-63% vs market
20082024
Equity ratio
26.1%
This company
38.2%
Market median
-32% vs market
20082024
Return on equity
-7.1%
This company
18.4%
Market median
-139% vs market
20082024
Net profit margin
-63.3%
This company
8.1%
Market median
-881% vs market
20082024
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20082024
Debt / equity
2.84×
This company
0.62×
Market median
-358% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
YP Deputy Member | Deputy Member | 2009 | — | — |
NT Chief Executive Officer | Chief Executive Officer | 1999 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2009 | — | — | |
| Board of Directors | 2009 | — | — | |
| Board of Directors | 2009 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Aximed Ab | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of AXIMED AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Yuk Ping Chan | Deputy Member | 0 companies |
| Nils Torsten Helsing | Chief Executive Officer | 0 companies |
| Gøran Carl Johan Høgstedt | Chairman | 0 companies |
| Geir Steinar Kvamsøe Knutsvik | Board of Directors | 0 companies |
| Hans Henrik Högstedt | Board of Directors | 0 companies |